Policy | August 03, 2022
She joins Enveda from Gilead Sciences
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Bayer now present in four of the largest biotechnology hubs in the United States
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Subscribe To Our Newsletter & Stay Updated
